Is Eli Lilly a Top AI-Driven Healthcare Stock for 2025?
Hedge funds are eyeing AI-powered healthcare plays, and Eli Lilly keeps coming up. Here's what investors should know.
If you've been paying attention to Wall Street lately, you've probably noticed two things dominating the conversation: artificial intelligence and weight-loss drugs. Eli Lilly sits at an interesting crossroads of both, which is why hedge funds keep putting it on their shortlists of AI-powered healthcare stocks worth owning.
So what does AI actually have to do with a pharmaceutical giant best known for Mounjaro and Zepbound? Quite a bit, it turns out. Drug companies are increasingly leaning on AI to speed up everything from molecule discovery to clinical trial design, and Eli Lilly has been investing heavily in that direction. For hedge funds, that combination of blockbuster drugs and tech-forward research makes the stock a compelling long-term bet.
Read more Samson Mow Calls Bitcoin Bottom Amid Analyst Doubts →
Hedge funds tend to cluster around stocks where they see durable competitive advantages — what investors call a "moat." Eli Lilly's dominance in the GLP-1 drug space, combined with its AI-assisted pipeline development, arguably gives it two moats for the price of one. That's the kind of story that gets portfolio managers excited enough to build meaningful positions.
Of course, no stock is a sure thing. Eli Lilly trades at a premium valuation, meaning a lot of future growth is already baked into the price. If the company's pipeline disappoints or competition in the obesity drug market heats up faster than expected, that lofty price tag could become a liability. Smart investors weigh that risk carefully before jumping in.
Whether LLY deserves a spot in your own portfolio depends on your risk tolerance and time horizon, but there's no denying it checks a lot of boxes that both AI enthusiasts and healthcare investors find attractive right now. Continue reading at Yahoo Finance.
